Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | Type 2 Diabetes |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
November 2024Filing acceptedCJC-1134-PCNMPA accepts the albenatide (CJC-1134-PC) marketing application in type 2 diabetes
CN, NMPA · Hebei Changshan Biochemical Pharmaceutical Co., Ltd · Source ↗
Financial reports
No financial reports recorded.